María Ángeles Foncillas

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui, Alessandro M. Vannucchi, Alberto Álvarez‐Larrán et al. · Leukemia · 2021 · 82 citations · Full text

Medicine, Hematology, Pharmacology +15

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

Tiziano Barbui, Valerio De Stefano, Alberto Álvarez‐Larrán et al. · Blood Cancer Journal · 2021 · 37 citations · Full text

Medicine, Hematology, Internal Medicine +16

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

Tomás Palanques-Pastor, Juan Eduardo Megías‐Vericat, Pilar Martı́nez et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2021 · 33 citations · Full text

Medicine, Infectious Diseases, Pharmacology +16

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience

Jorge Labrador, Miriam Saiz‐Rodríguez, Dunia de Miguel et al. · Cancers · 2022 · 30 citations · Full text

Medicine, Oncology, Pharmacology +15

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)

José Falantes, Lisa Pleyer, Sylvain Thépot et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2017 · 26 citations

Medicine, Oncology, Pharmacotherapy +11